Bicara Therapeutics rises after $150 mln equity raise

Bicara Therapeutics

25/02/2026 13:02

** Bicara Therapeutics BCAX.O shares up 4.2% in premarket trading at $16.93 after $150 mln overnight follow-on priced

** Boston, Massachusetts-based biopharma late Tues announced ~9.4 mln shares, including pre-funded warrants to buy 2.2 mln shares, at $16

** Offering price is 1.5% discount to stock's last sale on Tues

** Co intends to use net offering proceeds to support planned regulatory filing and commercial launch for ficerafusp alfa, its treatment for solid tumors, if approved, in the US, among other purposes

** Morgan Stanley, TD Cowen, BofA, Cantor and Stifel joint bookrunners

** Co has ~54.8 mln shares outstanding

** Through Tues close, stock rose ~15% over the past week, leaving it down 3.5% YTD

** 10 of 13 analysts rate the stock "strong buy" or "buy", 3 "hold"; median PT $30, per LSEG data

** BCAX went public in Sept 2024 IPO priced at $18

(Lance Tupper is a Reuters market analyst. The views expressed are his own)

((lance.tupper@tr.com 1-646-279-6380))